| 摘要 |
A method is described that computes the combined potency of a drug regimen based on predicted or in vitro determined dose-response response curves of the individual drugs in a treatment regimen. This is instrumental in those diagnostic situations where different instances of biomolecule sequences or other biomarkers are associated with a different, but measurable or predictable shape of the dose-response curve of one or more of the regimen drugs, and where the response to the drug can be translated to a (surrogate) clinical endpoint. |
